中文网站
on July 20th to conduct research and investigation. The delegation focused on in-depth discussions regarding silicon-based semiconductor biomedical chips, molecular POCT equipment R&D, the industrialization of domestic substitution, industrial synergy, and capital cooperation.
On-site Visit and Cooperation Exploration
Currently, Heping District of Tianjin is focusing on cultivating new productive forces in life and health, leveraging its fiscal and state-owned capital platforms to develop the high-end medical device sector. The domestic molecular detection industry is entering a window of opportunity for domestic substitution. BigFeiXu focuses on the R&D and mass production of advanced molecular detection products and silicon-based semiconductor biochips, holding a complete patent matrix both domestically and internationally, ranking among the top tier of domestic molecular detection companies and serving as a benchmark enterprise for domestic substitution.
Bao Shizheng, Director of the Finance Bureau of Heping District, Tianjin, Kong Ran, Director of the Investment Promotion Bureau of Heping District, Hou Yufeng, Secretary of the Party Committee and Chairman of Tianjin Quanye Hualian Group and Tianjin State-owned Capital Investment and Operation Co., Ltd., and others accompanied the delegation. Xie Lianyi, Founder, CEO/CTO of BigFeiXu, and his core team received the delegation.
Visiting Self-Developed Equipment
During the research visit, District Mayor Wang Xudong and his delegation toured the company's exhibition hall, chip laboratory, and production line. They listened to introductions about the company's technology layout, patent qualifications, star products, and market plans, and observed practical demonstrations.
Detailed Discussions
The company team introduced GeNext as the world's smallest end-to-end gene sequencing instrument, offering a 45-minute rapid test (15 minutes for the silicon-based version), at only 1/10th the cost of similar foreign instruments. It supports real-time Bluetooth/Wi-Fi communication and has a built-in power supply. It has received attention from *Nature* and has been selected for China's manned space program. The company has independently developed core MEMS ultrasonic/thermopile/optical detection chips, and developed high-sensitivity wide-area blood glucose CGM chips, brain-computer interface chips, and passive low-power chips. Many of its indicators are on par with and surpass those of international giants, filling the gap in China's high-end biochip market. It has already secured letters of intent from leading domestic companies for over 20 million biochips.
Xie Lianyi introduced the company's development plan. The company focuses on cutting-edge interdisciplinary technologies such as molecular POCT, possessing 47 domestic patents, 4 US patents, and 7 software copyrights. It holds complete CFDA/CE/FDA certifications; its 100-person R&D team comprises 90% with bachelor's, master's, or doctoral degrees. The global molecular detection market is projected to reach $40 billion in 2026, and the company expects a compound annual growth rate of approximately 28.5% in revenue from 2026 to 2030, indicating significant growth potential.
District Mayor Wang Xudong fully affirmed the achievements of Bigfei Sequence chip's independent R&D and the domestic substitution of high-end equipment. He stated that silicon-based biochips and molecular POCT are key areas for the integration of biotechnology and precision manufacturing, aligning with Heping District's industrial upgrading direction. Heping District will coordinate fiscal, state-owned asset, and investment resources to fully empower project implementation, industrial funds, and the expansion of channels in the northern market, promoting resource sharing and mutual benefit between the two regions' biopharmaceutical industries.
Post time: Jul-31-2026
Privacy settings